Questions?
(888) 391-1315

LATEST XARELTO UPDATE

Here's what's happening in 2017 with Xarelto...

Xarelto News & Updates Timeline

The anticoagulant drug Xarelto represents a new class of blood thinning medications meant to replace Coumadin and warfarin. With claims of fewer side effects and easier prescribing restrictions for patients, the joint effort from Bayer and Johnson & Johnson has already surpassed competitors Eliquis and Pradaxa with over $1 billion in sales.

However, the advent of these next-generation blood thinners hasn’t been all positive. Experts have weighed in with warnings that they may cause more serious internal bleeding risks than warfarin since there isn’t yet an antidote for severe hemorrhaging.

Consumer watchdog groups tracking adverse event reports to the FDA have noted thousands of patient complications, and several hundred deaths filed with the agency.

And now, with the number of lawsuits alleging internal bleeding hospitalization from Xarelto on the rise around the country, lawyers have asked that cases be moved to a special drug injury federal court.

xarelto latest news

2016

Timeline
13
NOV 2016

Judicial Panel for Multidistrict Litigation reports over 13,700 Xarelto lawsuits pending in Louisiana federal court alleging internal bleeding.

3
OCT 2016

American Medical Assoc. study finds patients taking Xarelto had higher rates of internal bleeding and death than those taking Pradaxa.

23
JUL 2016

Patient-Centered Outcomes Research Institute announces $6.5 million study to compare the safety of Xarelto, Pradaxa, Eliquis and Coumadin.

29
JUN 2016

Institute for Safe Medication Practices names Xarelto the most dangerous drug in the U.S., with over 10,000 complications reported to the FDA in 2015.

22
MAY 2016

Cambridge, Massachusetts study suggests competitor Savaysa may be more cost effective than Xarelto.

1
MAR 2016

New York Times report suggests Xarelto makers may have concealed data that measuring device used during clinical trials was defective.

1
FEB 2016

Duke University study shows internal bleeding incidents among Xarelto patients rose with the number of medications taken.

15
JAN 2016

Judicial Panel on Multidistrict Litigation reports 2,826 internal bleeding lawsuits now pending in Xarelto MDL court.

2015

Timeline
21
JAN 2015

Philladelphia judge creates second mass tort court for victims suffering internal bleeding after using Xarelto.

09
JAN 2015

U.S. based Portola Pharmaceuticals announces positive test results for its new drug andexanet alfa as a possible bleeding antidote for Xarelto.

07
JAN 2015

Study finds doctors were paid nearly $20 million to promote blood thinner drugs like Xarelto in just the last 5 months of 2013.

2014

Timeline
12
DEC 2014

JPML signs order consolidating Xarelto bleeding lawsuits to U.S. District Judge Eldon E. Fallon in the Eastern District Federal Court of Louisiana.

09
DEC 2014

Researchers from the University of Tel Aviv confirm Xarelto may have greater risks for intestinal bleeding than warfarin.

16
NOV 2014

Xarelto named among the top-5 fastest-growing drugs on the market

07
NOV 2014

Johnson & Johnson fights the consolidation of Xarelto bleeding lawsuits, claiming it will lead to more cases.

16
OCT 2014

Swiss researchers at the University of Basel establish a link between Xarelto use and liver damage.

15
OCT 2014

13,500 bottles of Xarelto are recalled by Johnson & Johnson and the FDA due to microbial contamination concerns FDA Enforcement Report.

14
OCT 2014

Sales of Xarelto top $1 billion for 2014. Johnson & Johnson Reports 2014 Third-Quarter Results.

09
OCT 2014

Lawyers representing at least 21 patients and families in over 10 states file petition to consolidate growing Xarelto lawsuits into specialized federal pharmaceutical injury court in Southern District of Illinois.

14
JUN 2014

Bayer admits it now faces at least 10 lawsuits in the United States alleging internal bleeding injury or death from Xarelto.

28
MAY 2014

Boehringer Ingelheim, maker of Xarelto competitor Pradaxa, announces it will pay $650 million to settle over 3,500 lawsuits alleging internal bleeding.

15
APR 2014

First lawsuit filed by family of patient alleging bleeding death from Xarelto.

14
APR 2014

Journal of the American Medical Association reports study suggesting blood thinners like Xarelto can double the risk of bleeding when taken with a non-steroidal anti-inflammatory or aspirin for pain or headache.

16
JAN 2014

The FDA votes unanimously against approving Xarelto for acute coronary syndrome (sudden blockage of blood to the heart).

2013

Timeline
21
NOV 2013

Findings presented at the American Heart Association 2013 Scientific Sessions suggest Xarelto causes three times higher risk of internal bleeding in acutely ill patients and four times higher risk of internal bleeding in patients with acute coronary syndrome (ACS).

18
OCT 2013

Anticoagulants including Xarelto ranked among the most dangerous drugs on the market by the Institute for Safe Medication Practices. Xarelto alone ranks 10th for side effects reported to FDA.

SEP 2013

German newspaper Der Speigel reports that German health officials have received 968 reports of adverse events involving Xarelto in the first eight months of 2013, including 72 deaths.

31
JUL 2013

Bayer and Johnson & Johnson report joint sales of Xarelto of $827 million for first half of 2013.

07
MAR 2013

Report in GastroJournal suggests newer anticoagulants like rivaroxaban (Xarelto) carry a 48% higher risk of gastrointestinal bleeding than standard care.

01
JAN 2013

FDA MedWatch adverse event recordings show 593 reports of bleeding linked to Xarelto by the end of 2012.

2012

Timeline
14
JUN 2012

Reuters publishes report showing first sign doctors are concerned with Xarelto bleeding safety.

2011

Timeline
04
NOV 2011

Xarelto approved by the FDA to prevent blood clots and resulting strokes in patients with the heart condition atrial fibrillation.

09
JUL 2011

Report in AHA Circulation Journal shows researchers searching for antidote for Xarelto internal bleeding. Prothrombin found to be possible agent.

01
JUL 2011

The FDA approves Xarelto for sale in the United States to prevent deep vein thrombosis (DVT) and resulting pulmonary embolism (PE) in patients that have undergone hip or knee replacement surgery.

2008

Timeline
SEP 2008

Xarelto approved by Health Canada to prevent venous thromboembolism (blood clots) in patients who have undergone hip or knee replacement surgery.